Special Issue "Advances and Challenges in Pharmacology for Cardiovascular Disease: Basic Pharmacological Studies and Translation"

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: closed (30 July 2023) | Viewed by 193

Special Issue Editors

Department of Pharmacology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Tiantan Xili 1, Dongcheng District, Beijing 100050, China
Interests: pharmacology; NAFLD/NASH; cardiovascular disease; zebrafish model; autophagy
1. Cerebrovascular Diseases Research Institute, Xuanwu Hospital of Capital Medical University, Beijing 100053, China
2. Beijing Geriatric Medical Research Center, Beijing 100053, China
3. Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing 100053, China
Interests: cerebrovascular disease; ischemic stroke; oxidative stress; autophagy

Special Issue Information

Dear Colleagues,

Cardiovascular disease is the leading cause of morbidity and mortality worldwide. With the sustained pandemic of the coronavirus disease 2019 (COVID-19), clinical outcomes are worse in COVID-19 patients with cardiovascular disease and risk factors. The novel coronavirus uses the ACE2 receptor for infection and impacts ACE2 function, and ACE2 carries major implications in most individuals with cardiovascular syndrome. COVID-19 can induce a high inflammation challenge leading to vascular inflammation, myocardial injury, venous thromboembolism, metabolic syndrome, etc. Due to this urgent demand, basic research and translational medicine are looking to break new ground. This Special Issue will discuss the possible mechanism, potential pharmacological strategy, and future perspectives on cardiovascular-related disease. In this topic, we welcome submissions of your latest research findings and reviews on the following subjects, but not limited to them: Discussing the mechanisms of cardiovascular-related disease associated with or without COVID-19; and discussing the efficacy and pharmacological mechanisms of biomolecular, small molecular, and natural products for cardiovascular-related disease.

Dr. Bo Chen
Dr. Yangmin Zheng
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • cardiovascular disease
  • inflammation
  • pharmacology
  • translational medicine
  • metabolic syndrome

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop